On Apr. 15, 2020, Vanda Pharma and Northwell Health’s research arm, The Feinstein Institutes for Medical Research, announced enrollment of the first patient in Vanda’s clinical trial, ODYSSEY VLY-686-3501 (NCT04326426), yesterday at Lenox Hill Hospital in New York City.

ODYSSEY is a Phase III double-blind placebo-controlled trial investigating the efficacy and safety of tradipitant, a neurokinin-1 receptor antagonist, in the treatment of neurogenic inflammation of the lung secondary to SARS-CoV-2 (COVID-19) infection.